Bayer Aktiengesellschaft (ETR:BAYN)
38.26
-0.02 (-0.04%)
At close: Mar 27, 2026
Bayer Aktiengesellschaft Employees
Bayer Aktiengesellschaft had 87,280 employees as of December 31, 2025. The number of employees decreased by 4,584 or -4.99% compared to the previous year.
Employees
87,280
Change
-4,584
Growth
-4.99%
Revenue / Employee
€522,170
Profits / Employee
€41,476
Market Cap
37.59B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 87,280 | -4,584 | -4.99% |
| Sep 30, 2025 | 88,502 | -5,743 | -6.09% |
| Jun 30, 2025 | 89,556 | -7,011 | -7.26% |
| Mar 31, 2025 | 90,885 | -7,304 | -7.44% |
| Dec 31, 2024 | 91,864 | -5,067 | -5.23% |
| Sep 30, 2024 | 94,245 | -6,628 | -6.57% |
| Jun 30, 2024 | 96,567 | -5,481 | -5.37% |
| Mar 31, 2024 | 98,189 | -3,546 | -3.49% |
| Dec 31, 2023 | 96,931 | -991 | -1.01% |
| Sep 30, 2023 | 100,873 | -1,423 | -1.39% |
| Jun 30, 2023 | 102,048 | 134 | 0.13% |
| Mar 31, 2023 | 101,735 | 982 | 0.97% |
| Dec 31, 2022 | 97,922 | 1,972 | 2.06% |
| Sep 30, 2022 | 102,296 | 2,482 | 2.49% |
| Jun 30, 2022 | 101,914 | 2,475 | 2.49% |
| Mar 31, 2022 | 100,753 | 1,424 | 1.43% |
| Dec 31, 2021 | 95,950 | -5 | -0.01% |
| Sep 30, 2021 | 99,814 | -804 | -0.80% |
| Jun 30, 2021 | 99,439 | -1,729 | -1.71% |
| Mar 31, 2021 | 99,329 | -2,872 | -2.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 178,583 |
| Fresenius Medical Care AG | 109,698 |
| Siemens Healthineers AG | 73,800 |
| Merck KGaA | 59,077 |
| Fielmann Group AG | 24,363 |
| Drägerwerk AG & Co. KGaA | 16,684 |
| Sartorius Aktiengesellschaft | 14,042 |
| Ottobock SE & Co. KGaA | 9,256 |
Bayer Aktiengesellschaft News
- 2 days ago - Bayer Crop Science Canada Redefines Canola Innovation With New ‘Advancing Better Canola’ Initiative - Financial Post
- 2 days ago - Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative - Business Wire
- 3 days ago - Multiplatinum Rapper, Actor Ludacris Partners with One A Day to Help People Realize that Health Does Not Need to Be Ludacris - Wallstreet:Online
- 5 days ago - Activist investor Inclusive Capital looks to sell stake in Bayer, Bloomberg News reports - Reuters
- 10 days ago - Formycon Secures Europe Launch Timing For FYB203 After Regeneron, Bayer Settlement - Nasdaq
- 10 days ago - EQS-News: Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer - Wallstreet:Online
- 12 days ago - Bayer Crop Science Launches 2026 Opportunity Scholarship Program - Business Wire
- 13 days ago - Bayer's Finerenone Meets Primary Endpoint In Phase 3 Study For Non-Diabetic Chronic Kidney Disease - Nasdaq